news
Hosted by https://biobizbuzz.com/ · news · EN-GB
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences. Disclaimer https://biobizbuzz.com/disclaimer/
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
31%
Guest openness
Selective
Sign up to generate a grounded pitch for BioBiz Buzz.
Signup to Generate a PitchBioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Recent episodes include "29. From overlooked science to investable biotech: The 2026 Strüngmann Award." (14 October 2026, 33 minutes), "28. Reawakening Wnt Biology: Neuvasq’s Approach to Restoring Retinal Vascular Integrity" (17 June 2026, 28 minutes), and "27. Microbiome Medicines at Scale: MRM Health’s Mission to Redefine Immune-Mediated Disease" (10 June 2026, 32 minutes).
BioBiz Buzz publishes roughly weekly, with episodes averaging 27 minutes across 29 episodes.
Booking probability for BioBiz Buzz is 31%, and the host is rated Selective on guests. BioBiz Buzz requires a Pod Score of 80 or higher. BioBiz Buzz's contact route on record: verified email.
The strongest fits for BioBiz Buzz are Scientific Research & Development and Pharmaceuticals. BioBiz Buzz has a news audience.
BioBiz Buzz is a news podcast with 29 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #1
What transforms a promising scientific opportunity into a viable biotechnology company? In this episode of BioBiz Buzz , Mike Ward speaks with Dr Jonathan Talbot, CEO of Melodia Therapeutics, co-founder and former CEO...
Episode #9
In this episode of BioBiz Buzz, your host Mike Ward explores a critical, but often underappreciated, driver of vision loss in retinal diseases; the breakdown of the blood–retina barrier (BRB). While anti-VEGF therapies...
Episode #7
<p>In this episode of BioBiz Buzz, Mike Ward talks to Dr Sam Possemiers, founder and CEO of Belgium-based MRM Health, about what it really takes to turn the human gut microbiome into a bona fide drug modality. They...
Episode #8
<p>Targeted protein degradation has moved from elegant academic concept to one of the most closely watched frontiers in oncology, promising to drug the 80% of disease‑driving proteins that traditional inhibitors and...
Episode #6
<p>For years, the narrative was simple: if you wanted a multibillion-dollar biotech outcome, you built in Boston or the Bay Area. Gilead’s up to $5 billion acquisition of Munich-based Tubulis just blew that up...
Episode #5
<p>Progress in developing safe and effective therapies for amyotrophic lateral sclerosis (ALS) has been painfully slow. It is caused by the death of motor neurons in the central nervous system and the spinal cord, which...
Episode #4
<p>What if an annual self-injection could silence your hidden cardiac risk instead of just lowering your LDL?</p><p>In this episode of BioBiz Buzz, Mike Ward sits down with David Solomon, CEO of Thalia Therapeutics, to...
Episode #3
<p>For more than three decades, transcription factors have been the great white whale of oncology drug discovery; tantalising, genetically validated, mechanistically central, and yet stubbornly out of reach. They sit at...
Episode #2
<p>Multiple myeloma remains the second-largest blood cancer globally with no cure, and despite recent breakthroughs in CAR-T and antibody therapies, patients continue to relapse, often losing the very antigens that...
Episode #1
<p>In this episode of BioBiz Buzz, your host Mike Ward sits down with Dr. Jared Baeten, Senior Vice President for Clinical Development and Head of the Virology Therapeutic Area at Gilead Sciences, to explore how new...
Episode #19
<p>2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down...
Episode #18
<p>Engineered T-cell receptor (TCR) therapies promise to do for solid tumours what chimeric antigen receptor T-cell (CAR-T) therapies have done for haematological malignancies.</p><p>The two approaches are conceptually...
Episode #17
<p>The traditional biotech funding model hasn't fundamentally changed in decades: brilliant founders with promising science face an impossible choice; build expensive internal R&D capabilities or negotiate partnerships...
Episode #16
<p>In a fundraising environment marked by cautious institutional investors, tightening belts, and widespread scepticism about early-stage venture capital, Sofinnova Partners has just closed its flagship Capital XI fund...
Episode #15
<p>This episode of BioBiz Buzz explores AL-S Pharma's pioneering approach to treating amyotrophic lateral sclerosis through AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1 protein. Host Mike Ward...
Episode #14
<p>GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge...
Episode #13
<p>Targeted protein degradation (TPD) represents one of the most transformative advances in drug discovery, with the global market projected to expand from USD 641 million in 2025 to as much as USD 9.85 billion by 2035...
Episode #12
<p>Breast cancer affects women of all ages after puberty in every country. In 2022, the disease struck an estimated 2.3 million women and claimed 670 000 lives globally, according to the World Health Organization. The...
Episode #11
<p>AI-based software solutions are increasingly being used as a second pair of eyes to help clinicians with the early diagnosis of diseases. With skin cancer seeing increasing rates of incidence and mortality, software...
Episode #10
<p>In a disease where hope has been scarce for decades, Belgian biotech Bioxodes is rewriting the rules of stroke treatment. Join your host Mike Ward in conversation with CEO Marc Dechamps as he reveals how his team...
Recent guests on BioBiz Buzz. Study who booked and why before you pitch.
business strategist, leadership consultant, and transformation expert, Lightspeed Technologies
Global Head of Life Sciences and Healthcare Thought Leadership, Australian Glass Group
Senior Teaching Associate in the Department of Politics and International Studies and Fellow of Selwyn College, University of Cambridge
founder of PicklePalz, University of Cape Town
PitchCentric classifies BioBiz Buzz under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
